
https://doi.org/10.1016/j.annonc.2020.01.002

Published in:
Annals of Oncology

Document Version:
Publisher’s PDF, also known as Version of record

Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal

Publisher rights
© 2020 The Authors.
This is an open access article published under a Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.

General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The Research Portal is Queen’s institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
CORRIGENDUM

Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial


1Department of Urology, The Christie and Salford Royal NHS Foundation Trusts, Manchester; 2Genito-Urinary Cancer Research Group, Division of Cancer Sciences, The University of Manchester, Manchester; 3MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London; 4London School of Hygiene and Tropical Medicine, London; 5UCL Cancer Institute, London; 6Guy’s and Saint Thomas’ NHS Foundation Trust, London; 7St James University Hospital, Leeds; 8Institute of Cancer Research, Sutton-London; 9Department of Radiology, University Hospitals Birmingham NHS Foundation Trust, Birmingham; 10Division of Cancer Sciences, The University of Manchester, Manchester; 11St James University Hospital, Leeds; 12Institute of Cancer Research and Cell Biology, Queen’s University Belfast, Belfast; 13East Lancashire Hospitals NHS Trust, Blackburn; 14Oxford University Hospitals NHS Foundation Trust, Oxford; 15Shrewsbury and Telford Hospital NHS Trust, Shrewsbury; 16University of Shefﬁeld, Shefﬁeld; 17Kent Oncology Centre, Maidstone; 18Lancashire Teaching Hospitals NHS Foundation Trust, Preston; 19Worcestershire Acute Hospitals NHS Trust, Worcester; 20Portsmouth Oncology Centre, Queen Alexandra Hospital, Portsmouth; 21Queen’s Hospital, Romford; 22Torbay and South Devon NHS Foundation Trust, Torbay; 23Sussex Cancer Centre, Brighton; 24Department of Oncology and Haematology, Kantonsspital, St Gallen, Switzerland; 25Centre for Cancer Research and Cell Biology, Queen’s University Belfast, Belfast; 26East Lancashire Hospitals NHS Trust, Blackburn; 27Oxford University Hospitals NHS Foundation Trust, Oxford; 28Shrewsbury and Telford Hospital NHS Trust, Shrewsbury; 29Yull and East Yorkshire Hospitals NHS Trust, Hull; 30Velindre Cancer Centre, Cardiff; 31Swansea University College of Medicine, Swansea; 32The Christie NHS Foundation Trust, Manchester; 33Heartlands Hospital, Birmingham; 34Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK

The authors regret that Fig.2F has been incorrectly titled. The correct title is “Failure-free survival high burden M1”.

DOI of original article: https://doi.org/10.1093/annonc/mdz396

Correspondence to: Prof. Noel W. Clarke, The Christie NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX, UK. Tel: +44 161 446 3364; Fax: +44 161 446 3365

E-mail: noel.clarke@christie.nhs.uk (N. W. Clarke).

0923-7534/© 2020 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).